Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOpredict-Lung neoadjuvant nivolumab-based therapy in resectable NSCLC
2019-002478-29Phase 2Active
- Sponsor
- Universitätsmedizin Essen
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and relatlimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Curatively intended surgery within 43 days. Started Jul 2019; status: active.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002478-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002478-29.